Pulmonary hypertension secondary to heart failure (HF‐PH) combined with pulmonary vascular remodeling has a high mortality rate. Apolipoprotein A1 (ApoA1) has been shown to adversely affect outcomes in patients with HF. A prospective follow‐up study was performed on 239 consecutive patients with HF‐PH who underwent right heart catheterization. Proteomics technology was used to analyze different proteins in plasma between post‐ and precapillary pulmonary hypertension (CpcPH) and isolated postcapillary pulmonary hypertension (IpcPH) filtered by propensity score matching. Ultimately, 175 patients were enrolled and followed for an average of 4.4 years. Lipoprotein components in plasma were measured, and the following clinical events were tracked. Proteomics data showed that lipid metabolism and inflammation were different between CpcPH and IpcPH. ApoA1 levels in HF‐PH patients with CpcPH were lower than those in HF‐PH patients with IpcPH. The patients with lower ApoA1 levels (≤1.025 g/L) were in a higher New York Heart Association class and had high levels of NT‐proBNP, mean pulmonary artery pressure, PVR, and diastolic pressure gradient. Besides, HF‐PH patients with lower ApoA1 levels had a 2.836‐fold higher relative risk of comorbid CpcPH compared with patients with higher ApoA1 levels. Moreover, patients with lower ApoA1 levels had a lower survival rate after adjusting for CpcPH. In conclusion, ApoA1 levels were negatively correlated with PVR levels. Lower ApoA1 levels were an independent risk factor for pulmonary vascular remodeling in HF‐PH patients. The survival of HF‐PH patients with lower ApoA1 levels was reduced.
Pulmonary arterial hypertension (PAH) is a fatal disease with limited available treatments and is characterized by pulmonary vascular remodeling. Substance P (SP) may be involved in vascular remodeling in patients with PAH. However, the underlying mechanism is currently unknown. In this study, we found that plasma SP levels were elevated and correlated with pulmonary hemodynamic parameters in PAH patients. SP receptor inhibitors significantly suppressed pulmonary vascular remodeling and improved pulmonary circulation hemodynamics in PAH rats. Multiple omics analyses suggested that downregulation of Fibulin‐2 (Fbln2) may play a role in promoting pulmonary vascular remodeling by SP. In addition, the downregulation of Fbln2 expression by SP was further verified by Western blot analysis and immunofluorescence. In vitro experiments showed that SP negatively regulated β‐catenin expression by downregulating Fbln2 expression. Moreover, SP promoted the DNA methylation of Fbln2. A methylation inhibitor alleviated SP mediated low expression of Fbln2 and high expression of β‐catenin. Overexpression of Fbln2 inhibited the proliferation and migration of pulmonary artery smooth muscle cells induced by SP. These data provide a novel mechanism through which SP promotes the proliferation and migration of PASMCs, leading to pulmonary hypertension and suggesting that Fbln2 is a potential therapeutic target for PAH.
Pulmonary hypertension caused by fibrosing mediastinitis (PH‐FM) is a high‐risk condition with limited validated tools for prognostic assessment. Although diffusing capacity of the lung for carbon monoxide (DLCO) predicts outcomes in several cardiopulmonary diseases, its prognostic value in PH‐FM remains unclear. In this multicenter retrospective cohort study, we included 106 patients with confirmed PH‐FM from 14 centers across China. The primary endpoint was all‐cause mortality. Cox proportional hazards models were used to assess the association between baseline percent‐predicted DLCO and mortality, with sequential adjustment for clinical, hemodynamic, and spirometric variables. The final cohort included 106 patients, of whom 60 had DLCO ≥ 60% predicted and 46 had DLCO < 60% predicted. Over a median follow‐up of 36 months (interquartile range [IQR], 14.0–50.8), 27 deaths occurred. Across Cox models, each 10‐percentage‐point increase in percent‐predicted DLCO was associated with a 30% lower risk of all‐cause mortality. DLCO < 60% predicted was associated with higher all‐cause mortality compared with DLCO ≥ 60% predicted, with hazard ratios ranging from 6.90 to 7.80 across models. Lower baseline percent‐predicted DLCO was independently associated with a higher risk of all‐cause mortality in patients with PH‐FM. DLCO may provide a simple, noninvasive measure to complement current risk assessment in this population.